Enliven Therapeutics ELVN EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's EPS (basic)?
- Enliven Therapeutics (ELVN) reported EPS (basic) of -$0.38 in Q1 2026.
- How has Enliven Therapeutics's EPS (basic) changed year-over-year?
- Enliven Therapeutics's EPS (basic) increased by 33.3% year-over-year, from -$0.57 to -$0.38.
- What is the long-term trend for Enliven Therapeutics's EPS (basic)?
- Over 4 years (2021 to 2025), Enliven Therapeutics's EPS (basic) has grown at a -5.9% compound annual growth rate (CAGR), from -$2.37 to -$1.86.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.